Free tool
FAERS Monitor: Boncresa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761456 or its brand name (Boncresa, Denosumab-Mobz). Reports on generic versions are filed under their own applications.
Reports
3
Serious
3
100% of reports
Hospitalization
1
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- abdominal pain upper1
- brain fog1
- cardiac failure1
- diarrhoea1
- dry skin1
- dyspnoea1
- fatigue1
- hypocalcaemia1
- neuropathy peripheral1
- osteosarcoma1
- tetany1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,156 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| osteosarcoma | 1 | 18276.2 | 3677.2 | 4,556 |
| tetany | 1 | 3847.6 | 776.1 | 960 |
| brain fog | 1 | 447.4 | 90.3 | 111 |
| hypocalcaemia | 1 | 370.4 | 74.8 | 92 |
| cardiac failure | 1 | 87.3 | 17.6 | 21 |
| neuropathy peripheral | 1 | 73.7 | 14.9 | 18 |
| dry skin | 1 | 52.5 | 10.6 | 12 |
| abdominal pain upper | 1 | 34.1 | 6.9 | 8 |
| dyspnoea | 1 | 12.4 | 2.5 | 2 |
| diarrhoea | 1 | 10.9 | 2.2 | 2 |
| fatigue | 1 | 9.0 | 1.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.